🔎 Trials Near Me

Beranda › Skleroderma Difus › Michigan

Uji klinis Skleroderma Difus di Michigan

7 studi untuk Skleroderma Difus mencari peserta di lokasi di Michigan.

Kota di Michigan

Teks studi resmi (Bahasa Inggris)

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

  • Uni Of Michigan Health System, Ann Arbor
  • Wayne State University, Detroit
  • Clinical Research Inst of MI, Saint Clair Shores
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06470048

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  • GSK Investigational Site, Ann Arbor
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

  • University of Michigan, Ann Arbor
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06195072

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

  • University of Michigan, Ann Arbor
Menerima pesertaFase 2/3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06328777

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

  • Nkarta Investigational Site, Ann Arbor
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06733935

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

  • Galderma Investigational Site # 8743, Ann Arbor
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Mar 2026 · NCT07047690

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

  • University of Michigan, Ann Arbor
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Jan 2026 · NCT06675344

Dari ClinicalTrials.gov, data diambil 4 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.